CLINICAL TRIALS PROFILE FOR GLUCAGON HYDROCHLORIDE

505(b)(2) Clinical Trials for GLUCAGON HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT04520490 ↗	Brain Activation and Satiety in Children 2	Recruiting	University of Washington	Phase 3	2021-01-28	Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
New Combination	NCT04520490 ↗	Brain Activation and Satiety in Children 2	Recruiting	Seattle Children's Hospital	Phase 3	2021-01-28	Childhood obesity and related long-term effects are serious public health problems, but not all children with obesity do well in treatment. This study will test a new combination of family-based behavioral treatment (FBT) with a drug intervention using a glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide once weekly extended-release (ExQW, Bydureon®) in order to improve obesity intervention outcomes in 10-12-year-old children.
New Formulation	NCT05206149 ↗	Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes	Completed	Azienda Ospedaliera Città della Salute e della Scienza di Torino	Phase 4	2021-10-01	The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function, representing a stimulus for both the corticotropic and somatotropic axis, substantially safe and easily available. The standard procedure involves the intramuscular injection of 1-1.5 mg of glucagon based on the patient's weight. In addition to its antero-pituitary function, glucagon has also shown its ability to stimulate neurohypophyseal secretion. Using the copeptin dosage, it has been shown that after the administration of glucagon in healthy subjects there is a significant release of ADH. However, the available data are scarse and there is no standardized protocol for the use of the glucagon test in diabetes insipidus. At the moment, GST is not the most frequently chosen diagnostic option. In fact, despite having the advantage of being able to investigate different areas of anterohypophyseal and probably posterohypophyseal function at the same time, the test has some disadvantages: the prolonged duration makes the procedure challenging, the intramuscular injection can be unwelcome, and many variables can come into play in the definition of a normal response (age, BMI, glycemic status). The recent introduction of a single-dose nasal powder formulation (Baqsimi®) could overcome some of the limitations of classic GST and make the procedure less demanding. To date, no assessments are yet available regarding a purely diagnostic role in the context of hypopituitarism of this new formulation. Through the knowledge of the physiological response of the adrenocortical, somatotropic and ADH axis to the administration of intranasal glucagon in healthy subjects, it will be possible to evaluate its possible application in the diagnosis of GH deficiency, central adrenal insufficiency and possibly diabetes insipidus.

All Clinical Trials for GLUCAGON HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005889 ↗	Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion	Unknown status	Baylor College of Medicine	N/A	1999-10-01	RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00005889 ↗	Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion	Unknown status	National Center for Research Resources (NCRR)	N/A	1999-10-01	RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00013910 ↗	NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes	Completed	National Center for Research Resources (NCRR)	Phase 1	1969-12-31	The purpose of this research study is to investigate the mechanism of action of a new investigational medication (drug), NNC 90-1170, which is being developed for the treatment of type 2 diabetes (adult onset type of diabetes. NNC 90-1170 is a modified form of a hormone, Glucagon-Like Peptide 1 (or GLP-1), which is important for controlling insulin levels. Insulin, another hormone, is also important for controlling blood glucose levels, which are higher than normal in people who have type 2 diabetes. This study will measure the effect of NNC 90-1170, active investigational drug, to cause insulin to be released from the pancreas in response to increasing blood glucose concentrations. These results will be compared to that of a group of healthy volunteers of similar age and body weight who do not have diabetes. Also, various other hormones and substances that are known to control blood sugar will be measured in blood samples that will be drawn. One dose of NNC 90-1170 will be given to subjects with type 2 diabetes only in this study, and the effects of this dose will be compared to a placebo (inactive substance that looks like the active drug). This is a crossover study, which means that subjects will be treated both with NNC 90-1170 and with placebo. The order in which subjects will receive the treatments will be determined by chance (randomly). The study will be conducted as a so-called "double-blind" study, meaning that neither subjects nor study doctors will know the order in which subjects will be given each treatment until the study is over. The study will include approximately 15 healthy volunteers and 15 volunteers with type 2 diabetes, and it will be conducted at 1 clinic (the University of Michigan Health System) in the United States.
NCT00064714 ↗	Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2003-07-01	This study will determine 1) the safety of AC2993 in patients with type I diabetes; 2) the ability of AC2993 to improve beta cell function; and 3) the effects of immunosuppression on beta cell function. Type I diabetes is an autoimmune disease, in which the immune system attacks the beta cells of the pancreas. These cells produce insulin, which regulates blood sugar. AC2993 may improve the pancreas's ability to produce insulin and help control blood sugar, but it may also activate the original immune response that caused the diabetes. Thus, this study will examine the effects of AC2993 alone as well as in combination with immunosuppressive drugs. Patients between 18 and 60 years of age who have type I diabetes mellitus may be eligible for this 20-month study. They must have had diabetes for at least 5 years and require insulin treatment. Candidates will be screened with a questionnaire, followed by medical history and physical examination, blood and urine tests, a chest x-ray and skin test for tuberculosis, electrocardiogram (EKG), and arginine stimulated C-peptide test (see description below). Participants will undergo the following tests and procedures: Advanced screening phase: Participants undergo a diabetes education program, including instruction on frequent blood glucose monitoring, dietary education on counting carbohydrates, intensive insulin therapy, review of signs and symptoms of low blood sugar (hypoglycemia), and potential treatment with glucagon shots. Patients must administer insulin via an insulin pump or take at least four injections per day including glargine (Lantus) insulin. 4-month run-in phase - Arginine-stimulated C-peptide test: This test measures the body's insulin production. The patient is injected with a liquid containing arginine, a normal constituent of food that increases insulin release from beta cells into the blood stream. After the injection, seven blood samples are collected over 10 minutes. - Mixed meal stimulated C-peptide test with acetaminophen: This test assesses the response of the beta cells to an ordinary meal and the time it takes for food to pass through the stomach. The patient drinks a food supplement and takes acetaminophen (Tylenol). Blood samples are then drawn through a catheter (plastic tube placed in a vein) every 30 minutes for 4 hours to measure levels of various hormones and the concentration of acetaminophen. - Euglycemic clamp: This test measures the body's level of insulin resistance by measuring the amount of glucose necessary to compensate for an increased insulin level while maintaining a prespecified blood glucose level.
NCT00064714 ↗	Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes	Completed	AstraZeneca	Phase 2	2003-07-01	This study will determine 1) the safety of AC2993 in patients with type I diabetes; 2) the ability of AC2993 to improve beta cell function; and 3) the effects of immunosuppression on beta cell function. Type I diabetes is an autoimmune disease, in which the immune system attacks the beta cells of the pancreas. These cells produce insulin, which regulates blood sugar. AC2993 may improve the pancreas's ability to produce insulin and help control blood sugar, but it may also activate the original immune response that caused the diabetes. Thus, this study will examine the effects of AC2993 alone as well as in combination with immunosuppressive drugs. Patients between 18 and 60 years of age who have type I diabetes mellitus may be eligible for this 20-month study. They must have had diabetes for at least 5 years and require insulin treatment. Candidates will be screened with a questionnaire, followed by medical history and physical examination, blood and urine tests, a chest x-ray and skin test for tuberculosis, electrocardiogram (EKG), and arginine stimulated C-peptide test (see description below). Participants will undergo the following tests and procedures: Advanced screening phase: Participants undergo a diabetes education program, including instruction on frequent blood glucose monitoring, dietary education on counting carbohydrates, intensive insulin therapy, review of signs and symptoms of low blood sugar (hypoglycemia), and potential treatment with glucagon shots. Patients must administer insulin via an insulin pump or take at least four injections per day including glargine (Lantus) insulin. 4-month run-in phase - Arginine-stimulated C-peptide test: This test measures the body's insulin production. The patient is injected with a liquid containing arginine, a normal constituent of food that increases insulin release from beta cells into the blood stream. After the injection, seven blood samples are collected over 10 minutes. - Mixed meal stimulated C-peptide test with acetaminophen: This test assesses the response of the beta cells to an ordinary meal and the time it takes for food to pass through the stomach. The patient drinks a food supplement and takes acetaminophen (Tylenol). Blood samples are then drawn through a catheter (plastic tube placed in a vein) every 30 minutes for 4 hours to measure levels of various hormones and the concentration of acetaminophen. - Euglycemic clamp: This test measures the body's level of insulin resistance by measuring the amount of glucose necessary to compensate for an increased insulin level while maintaining a prespecified blood glucose level.

Clinical Trial Conditions for GLUCAGON HYDROCHLORIDE

Condition Name

Condition Name for GLUCAGON HYDROCHLORIDE
Intervention	Trials
Type 2 Diabetes	101
Obesity	90
Type 2 Diabetes Mellitus	75
Type 1 Diabetes	67

Condition MeSH

Condition MeSH for GLUCAGON HYDROCHLORIDE
Intervention	Trials
Diabetes Mellitus	366
Diabetes Mellitus, Type 2	282
Diabetes Mellitus, Type 1	149
Hypoglycemia	81

Clinical Trial Locations for GLUCAGON HYDROCHLORIDE

Trials by Country

Trials by Country for GLUCAGON HYDROCHLORIDE
Location	Trials
United States	771
Denmark	113
China	91
Canada	70
Germany	50

Trials by US State

Trials by US State for GLUCAGON HYDROCHLORIDE
Location	Trials
Texas	72
California	57
New York	44
Pennsylvania	36
Minnesota	35

Clinical Trial Progress for GLUCAGON HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for GLUCAGON HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	35
PHASE3	13
PHASE2	25

Clinical Trial Status

Clinical Trial Status for GLUCAGON HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	484
RECRUITING	147
Unknown status	82

Clinical Trial Sponsors for GLUCAGON HYDROCHLORIDE

Sponsor Name

Sponsor Name for GLUCAGON HYDROCHLORIDE
Sponsor	Trials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	53
Novo Nordisk A/S	40
University Hospital, Gentofte, Copenhagen	33

Sponsor Type

Sponsor Type for GLUCAGON HYDROCHLORIDE
Sponsor	Trials
Other	1123
Industry	350
NIH	93

Glucagon Hydrochloride: Clinical Trial Landscape and Market Projections

Last updated: February 19, 2026

What is the current status of Glucagon Hydrochloride clinical trials?

Glucagon Hydrochloride is an established therapeutic agent used for treating hypoglycemia, primarily in diabetic patients. Its primary mechanism of action is to increase blood glucose levels by stimulating glycogenolysis and gluconeogenesis in the liver. The landscape of clinical trials for Glucagon Hydrochloride is predominantly focused on novel formulations, delivery methods, and expanded indications, rather than on the core molecule's efficacy for its primary indication.

Existing trials aim to improve patient convenience and expand the utility of glucagon for emergency management of severe hypoglycemia. These include studies evaluating ready-to-use formulations, nasal spray devices, and autoinjectors. For instance, studies have investigated the pharmacokinetics and pharmacodynamics of different glucagon formulations to establish bioequivalence and assess safety profiles. Trials also explore glucagon's potential in managing other conditions, such as diagnostic imaging and adjunctive therapy in certain surgical procedures.

A significant area of development is the stabilization of glucagon for longer shelf life at room temperature, a key barrier to wider adoption of ready-to-use preparations. Research into lyophilized powders and liquid formulations with improved stability is ongoing.

Table 1: Key Glucagon Hydrochloride Clinical Trial Areas

Trial Area	Focus
New Formulations	Ready-to-use liquid solutions, lyophilized powders, stable liquid formulations.
Delivery Devices	Nasal sprays, pre-filled syringes, autoinjectors, microneedle patches.
Expanded Indications	Diagnostic imaging (radiology), adjunctive therapy in surgical settings, management of refractory hypotension.
Comparative Efficacy	Head-to-head comparisons with existing emergency glucose-raising agents.
Patient Usability	Ease of administration, training requirements, and patient/caregiver preference for different devices.

The regulatory pathway for these advancements typically involves demonstrating bioequivalence to existing approved products, alongside robust safety data and improved product attributes. For novel indications, rigorous efficacy and safety studies are required.

What is the projected market size and growth for Glucagon Hydrochloride?

The global Glucagon Hydrochloride market is projected to experience steady growth, driven by the increasing prevalence of diabetes and the demand for more convenient and accessible emergency hypoglycemia treatments. The market is also influenced by advancements in drug delivery systems and the exploration of new therapeutic applications.

The current market is characterized by the established use of glucagon for severe hypoglycemia. The primary drivers for market expansion include:

• Rising Diabetes Prevalence: The global increase in type 1 and type 2 diabetes mellitus directly expands the patient population at risk for severe hypoglycemia requiring emergency glucagon treatment. The International Diabetes Federation (IDF) estimates that 537 million adults were living with diabetes in 2021, projected to reach 643 million by 2030 and 700 million by 2045 [1].
• Demand for Convenience: The limitations of traditional glucagon kits, which require reconstitution and injection, have spurred demand for ready-to-use formulations and alternative delivery methods like nasal sprays and autoinjectors. These offer faster administration and reduce the burden on caregivers in emergency situations.
• Technological Advancements: Innovations in drug formulation and device technology are making glucagon more stable, user-friendly, and accessible. This includes room-temperature stable liquid formulations and devices designed for rapid, intuitive use.
• Exploration of New Indications: While hypoglycemia remains the primary indication, ongoing research into glucagon's role in other areas, such as diagnostic imaging and potential cardiovascular benefits, could unlock new market segments.

The market is segmented by product type (injection kits, nasal sprays, autoinjectors), formulation (powder for reconstitution, ready-to-use liquid), and end-user (hospitals, pharmacies, home care). The injection kits segment currently dominates, but the nasal spray and autoinjector segments are expected to grow at a higher CAGR due to their improved convenience.

Table 2: Glucagon Hydrochloride Market Projections (USD Billion)

Year	Market Size	Compound Annual Growth Rate (CAGR)
2023	1.2	N/A
2024	1.3	8.3%
2025	1.4	7.7%
2026	1.5	7.1%
2027	1.6	6.7%
2028	1.7	6.3%

Note: Projections are estimates based on current trends and market analyses.

The competitive landscape includes established pharmaceutical companies and emerging biotechnology firms developing novel glucagon formulations and delivery systems. Key players are focusing on R&D to gain market share through product differentiation and expanding market access.

What are the key regulatory considerations for Glucagon Hydrochloride products?

Regulatory pathways for Glucagon Hydrochloride products are governed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The specific regulatory requirements depend on whether the product is a new formulation, a new delivery device, or an application for a new indication.

For new formulations or delivery devices of existing Glucagon Hydrochloride, the primary regulatory hurdle is often demonstrating equivalence to an already approved product. This typically involves:

• Bioequivalence Studies: These studies compare the rate and extent of drug absorption from the new formulation/device to a reference product. The goal is to show that the new product delivers the same amount of active drug to the bloodstream over time.
• Product Performance: For novel devices, manufacturers must demonstrate the device's reliability, accuracy, and safety of operation. This includes usability testing with target patient populations and healthcare professionals.
• Stability Studies: Manufacturers must provide comprehensive stability data to support the proposed shelf life and storage conditions for the product. This is particularly critical for liquid formulations aiming for room-temperature stability.
• Manufacturing and Quality Control: Adherence to Good Manufacturing Practices (GMP) is essential. This includes robust quality control measures to ensure product consistency and purity.

For new indications, Glucagon Hydrochloride would typically undergo a more extensive clinical trial process similar to the development of a novel drug. This would involve:

• Preclinical Studies: In vitro and in vivo studies to establish the mechanism of action and initial safety profile for the new indication.
• Phase 1 Trials: Safety and pharmacokinetic studies in healthy volunteers or patients with the target condition.
• Phase 2 Trials: Dose-ranging and preliminary efficacy studies in patients with the target condition.
• Phase 3 Trials: Large-scale, randomized, controlled trials to confirm efficacy and safety for the new indication.

Key Regulatory Considerations:

• Route of Administration: Different routes of administration (e.g., intramuscular, subcutaneous, nasal) are subject to specific device-related and formulation-related regulatory scrutiny.
• Indication Specificity: Approval is tied to specific indications. Any expansion requires separate regulatory review and approval.
• Pediatric Use: Data on the efficacy and safety of glucagon in pediatric populations, particularly for new formulations or devices, is often a critical requirement.
• Labeling and Prescribing Information: Clear and accurate labeling, including instructions for use, storage, and emergency management, is paramount.

The regulatory landscape is dynamic, with agencies increasingly focusing on patient-centric drug development, including the usability and convenience of drug delivery systems. Companies must engage early with regulatory authorities to navigate these requirements effectively.

What are the main competitive challenges and opportunities for Glucagon Hydrochloride manufacturers?

The Glucagon Hydrochloride market presents a competitive landscape shaped by established players and emerging innovators. Manufacturers face challenges related to product differentiation, market access, and the development of novel delivery systems, while also identifying opportunities for growth through innovation and expanded indications.

Competitive Challenges:

• Product Commoditization: For traditional glucagon injection kits, there is a risk of product commoditization, where price becomes a primary competitive factor, impacting profit margins.
• Competition from Alternative Treatments: While glucagon is unique for its rapid action in severe hypoglycemia, other methods of managing blood glucose are continuously evolving. This includes advanced continuous glucose monitoring (CGM) systems with low-glucose alerts and automated insulin delivery systems that can help prevent severe lows.
• Reimbursement and Market Access: Securing favorable reimbursement from payers can be challenging, especially for new, higher-priced formulations or devices. Demonstrating significant clinical utility and cost-effectiveness is crucial.
• Intellectual Property Landscape: The patent landscape for glucagon and its delivery systems can be complex, requiring careful navigation to avoid infringement and to protect proprietary innovations.
• Manufacturing Complexity: Developing and manufacturing stable, ready-to-use liquid formulations or advanced delivery devices can involve complex scientific and engineering challenges, requiring significant investment.

Market Opportunities:

• Innovation in Delivery Devices: The most significant opportunity lies in developing and commercializing user-friendly, rapid-acting, and room-temperature stable delivery devices. Nasal sprays and autoinjectors are key areas of growth, addressing unmet patient needs for convenience and ease of use.
• Expansion into New Indications: Research into glucagon's potential in areas beyond hypoglycemia management, such as diagnostic imaging, could open new revenue streams. Studies exploring its use in conditions like paralytic ileus or as a contrast agent in radiology represent potential growth avenues.
• Combination Therapies: Investigating glucagon in combination with other agents for specific therapeutic goals could create new market niches.
• Geographic Expansion: Targeting emerging markets with increasing diabetes prevalence and a growing demand for advanced healthcare solutions offers significant growth potential.
• Partnerships and Collaborations: Strategic partnerships between pharmaceutical companies, device manufacturers, and research institutions can accelerate innovation and market penetration.

The ability to secure robust intellectual property protection for novel formulations and delivery devices will be critical for maintaining a competitive edge. Companies that can effectively address the unmet needs of patients and healthcare providers through superior product attributes are best positioned for success.

What are the key unmet needs in Glucagon Hydrochloride therapy?

Despite its established role, Glucagon Hydrochloride therapy still has several key unmet needs that present opportunities for innovation and market development. These primarily revolve around the practical aspects of administration, product stability, and accessibility.

• Ease of Administration: Traditional glucagon kits require preparation (mixing powder with diluent) and injection, which can be challenging for non-medical personnel, especially in emergency situations. This is a significant barrier for caregivers and individuals with limited dexterity or training.
• Product Stability and Storage: Many glucagon formulations require refrigeration and have a limited shelf life once reconstituted. This poses logistical challenges for storage at home, in schools, workplaces, and while traveling. The development of stable, room-temperature formulations is a critical unmet need.
• Speed and Reliability of Emergency Treatment: While glucagon acts quickly, the time taken to prepare and administer the injection can be a factor in critical hypoglycemia events. Devices that ensure rapid and foolproof administration are highly desirable.
• Patient and Caregiver Comfort and Confidence: The injection itself can be a source of anxiety for patients and caregivers. Alternative delivery methods that are less invasive or intimidating could improve adherence and reduce psychological barriers.
• Accessibility and Affordability: Ensuring that glucagon is readily available and affordable for all individuals at risk of severe hypoglycemia remains an ongoing challenge. This includes issues related to insurance coverage and equitable distribution.
• Limited Utility Beyond Severe Hypoglycemia: While primarily used for severe hypoglycemia, exploring and validating glucagon's efficacy and safety in other potential therapeutic areas could broaden its clinical utility and address other medical needs.

Addressing these unmet needs through advancements in formulation science, delivery device technology, and broader market access strategies will be crucial for the continued evolution and success of Glucagon Hydrochloride therapeutics.

Key Takeaways

• Glucagon Hydrochloride clinical trials are focused on improving delivery systems (nasal sprays, autoinjectors) and stability for ready-to-use formulations, alongside exploring new therapeutic indications.
• The global Glucagon Hydrochloride market is projected to grow steadily, driven by rising diabetes prevalence and demand for convenient emergency treatments, with an estimated market size of $1.7 billion by 2028.
• Regulatory pathways involve demonstrating bioequivalence for new formulations/devices and rigorous clinical trials for new indications, with a focus on safety, efficacy, and product performance.
• Key competitive challenges include product commoditization and reimbursement hurdles, while opportunities lie in innovative delivery devices, new indications, and geographic expansion.
• Major unmet needs in Glucagon Hydrochloride therapy include enhancing ease of administration, improving product stability for room-temperature storage, and increasing accessibility and affordability.

Frequently Asked Questions

1. What are the primary advantages of nasal glucagon formulations over traditional injection kits? Nasal glucagon formulations offer advantages such as ease of administration, as they do not require reconstitution or injection, reducing the barrier for untrained individuals. They are also designed for rapid delivery and can potentially be stored at room temperature, offering greater convenience.

2. Are there any significant side effects associated with Glucagon Hydrochloride? Common side effects include nausea and vomiting. Transient increases in heart rate and blood pressure can also occur. In rare cases, hypersensitivity reactions are possible.

3. What is the typical shelf life of Glucagon Hydrochloride products? Traditional glucagon kits (powder for reconstitution) generally have a longer shelf life when stored as directed (often refrigerated). Once reconstituted, the solution typically has a limited stability, often requiring use within 24-48 hours and refrigeration. Newer ready-to-use liquid formulations aim for longer shelf lives at room temperature, but specific product stability varies.

4. How does Glucagon Hydrochloride differ from injectable glucose or oral glucose treatments for hypoglycemia? Glucagon Hydrochloride works by mobilizing the body's own glucose reserves stored in the liver (glycogen), leading to a rapid increase in blood glucose levels. Injectable glucose (like dextrose solution) directly introduces glucose into the bloodstream. Oral glucose treatments (like glucose tablets or juice) rely on absorption from the gastrointestinal tract. Glucagon is particularly effective for severe hypoglycemia when the individual is unconscious or unable to swallow.

5. What is the role of glucagon in diagnostic imaging? Glucagon can be used in diagnostic imaging, particularly in gastrointestinal radiology. Its smooth muscle relaxant properties can help reduce peristalsis in the intestines and stomach, which can improve the visualization of these organs during procedures such as barium studies or CT scans, allowing for clearer images.

Citations

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas 10th edition 2021. Retrieved from https://www.diabetesatlas.org/